OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
An adipocentric perspective on the development and progression of non-alcoholic fatty liver disease
Eun Young Lee, Hannelie Korf, Antonio Vidal‐Puig
Journal of Hepatology (2023) Vol. 78, Iss. 5, pp. 1048-1062
Open Access | Times Cited: 96
Eun Young Lee, Hannelie Korf, Antonio Vidal‐Puig
Journal of Hepatology (2023) Vol. 78, Iss. 5, pp. 1048-1062
Open Access | Times Cited: 96
Showing 1-25 of 96 citing articles:
The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease
Luis Antonio Díaz, Juan Pablo Arab, Alexandre Louvet, et al.
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 20, Iss. 12, pp. 764-783
Closed Access | Times Cited: 87
Luis Antonio Díaz, Juan Pablo Arab, Alexandre Louvet, et al.
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 20, Iss. 12, pp. 764-783
Closed Access | Times Cited: 87
An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD)
Michèle Vacca, Ioannis Kamzolas, Lea Mørch Harder, et al.
Nature Metabolism (2024) Vol. 6, Iss. 6, pp. 1178-1196
Open Access | Times Cited: 50
Michèle Vacca, Ioannis Kamzolas, Lea Mørch Harder, et al.
Nature Metabolism (2024) Vol. 6, Iss. 6, pp. 1178-1196
Open Access | Times Cited: 50
Role of Insulin Resistance in the Development of Nonalcoholic Fatty Liver Disease in People With Type 2 Diabetes: From Bench to Patient Care
Juan Patricio Nogueira, Kenneth Cusi
Diabetes Spectrum (2024) Vol. 37, Iss. 1, pp. 20-28
Open Access | Times Cited: 37
Juan Patricio Nogueira, Kenneth Cusi
Diabetes Spectrum (2024) Vol. 37, Iss. 1, pp. 20-28
Open Access | Times Cited: 37
SCD1 is the critical signaling hub to mediate metabolic diseases: Mechanism and the development of its inhibitors
Qin Sun, Xiaorui Xing, Huanyu Wang, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 170, pp. 115586-115586
Open Access | Times Cited: 36
Qin Sun, Xiaorui Xing, Huanyu Wang, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 170, pp. 115586-115586
Open Access | Times Cited: 36
Gastrointestinal cancers in lean individuals with non‐alcoholic fatty liver disease: A systematic review and meta‐analysis
Matheus Souza, Ivanna Diaz, Ilaria Barchetta, et al.
Liver International (2023) Vol. 44, Iss. 1, pp. 6-14
Open Access | Times Cited: 25
Matheus Souza, Ivanna Diaz, Ilaria Barchetta, et al.
Liver International (2023) Vol. 44, Iss. 1, pp. 6-14
Open Access | Times Cited: 25
Cdo1-Camkk2-AMPK axis confers the protective effects of exercise against NAFLD in mice
Min Chen, Jieying Zhu, Wang-Jing Mu, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 22
Min Chen, Jieying Zhu, Wang-Jing Mu, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 22
Unraveling Adipose Tissue Dysfunction: Molecular Mechanisms, Novel Biomarkers, and Therapeutic Targets for Liver Fat Deposition
Marta Lopez‐Yus, C. Hörndler, Sofía Borlán, et al.
Cells (2024) Vol. 13, Iss. 5, pp. 380-380
Open Access | Times Cited: 10
Marta Lopez‐Yus, C. Hörndler, Sofía Borlán, et al.
Cells (2024) Vol. 13, Iss. 5, pp. 380-380
Open Access | Times Cited: 10
Role of lifestyle and glucagon‐like peptide‐1 receptor agonists for weight loss in obesity, type 2 diabetes and steatotic liver diseases
Anna Giannakogeorgou, Michael Roden
Alimentary Pharmacology & Therapeutics (2024) Vol. 59, Iss. S1
Open Access | Times Cited: 10
Anna Giannakogeorgou, Michael Roden
Alimentary Pharmacology & Therapeutics (2024) Vol. 59, Iss. S1
Open Access | Times Cited: 10
Phenotypes of Metabolic Dysfunction–Associated Steatotic Liver Disease–Associated Hepatocellular Carcinoma
Jesús Rivera‐Esteban, Sergio Muñoz, Mónica Higuera, et al.
Clinical Gastroenterology and Hepatology (2024) Vol. 22, Iss. 9, pp. 1774-1789.e8
Closed Access | Times Cited: 8
Jesús Rivera‐Esteban, Sergio Muñoz, Mónica Higuera, et al.
Clinical Gastroenterology and Hepatology (2024) Vol. 22, Iss. 9, pp. 1774-1789.e8
Closed Access | Times Cited: 8
Dissecting Acute Drug‐Induced Hepatotoxicity and Therapeutic Responses of Steatotic Liver Disease Using Primary Mouse Liver and Blood Cells in a Liver‐On‐A‐Chip Model
Hanyang Liu, Yin Guo, Marlene Kohlhepp, et al.
Advanced Science (2024) Vol. 11, Iss. 30
Open Access | Times Cited: 7
Hanyang Liu, Yin Guo, Marlene Kohlhepp, et al.
Advanced Science (2024) Vol. 11, Iss. 30
Open Access | Times Cited: 7
An adipocentric perspective of pancreatic lipotoxicity in diabetes pathogenesis
Renata Risi, Antonio Vidal‐Puig, Guillaume Bidault
Journal of Endocrinology (2024) Vol. 262, Iss. 1
Open Access | Times Cited: 6
Renata Risi, Antonio Vidal‐Puig, Guillaume Bidault
Journal of Endocrinology (2024) Vol. 262, Iss. 1
Open Access | Times Cited: 6
MetALD: Does it require a different therapeutic option?
George Marek, Harmeet Malhi
Hepatology (2024) Vol. 80, Iss. 6, pp. 1424-1440
Closed Access | Times Cited: 5
George Marek, Harmeet Malhi
Hepatology (2024) Vol. 80, Iss. 6, pp. 1424-1440
Closed Access | Times Cited: 5
Epigallocatechin gallate alleviates Non-alcoholic fatty liver disease through the inhibition of the expression and activity of Dipeptide kinase 4
Mingfeng Yang, Ruike Yan, Ruohe Sha, et al.
Clinical Nutrition (2024) Vol. 43, Iss. 8, pp. 1769-1780
Closed Access | Times Cited: 5
Mingfeng Yang, Ruike Yan, Ruohe Sha, et al.
Clinical Nutrition (2024) Vol. 43, Iss. 8, pp. 1769-1780
Closed Access | Times Cited: 5
The association between the non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio and non-alcoholic fatty liver disease in US adults: a cross-sectional study
Xudong Huang, Jing Li, Lifeng Zhang, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 5
Xudong Huang, Jing Li, Lifeng Zhang, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 5
Multi-omics reveals the mechanism of Trimethylamine N-oxide derived from gut microbiota inducing liver fatty of dairy cows
Chenlei Li, Feifei Wang, Yongxia Mao, et al.
BMC Genomics (2025) Vol. 26, Iss. 1
Open Access
Chenlei Li, Feifei Wang, Yongxia Mao, et al.
BMC Genomics (2025) Vol. 26, Iss. 1
Open Access
Why weight loss is only half the battle: the epigenetic memory of adipose tissue
Valerie Chew
Journal of Hepatology (2025)
Closed Access
Valerie Chew
Journal of Hepatology (2025)
Closed Access
In Vivo and In Vitro Models of Hepatic Fibrosis for Pharmacodynamic Evaluation and Pathology Exploration
Yanting Hu, Zhongrui Zhang, Akida Adiham, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 2, pp. 696-696
Open Access
Yanting Hu, Zhongrui Zhang, Akida Adiham, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 2, pp. 696-696
Open Access
Adipokines regulate the development and progression of MASLD through organellar oxidative stress
Ke Zhao, Heng Zhang, Wenyu Ding, et al.
Hepatology Communications (2025) Vol. 9, Iss. 2
Open Access
Ke Zhao, Heng Zhang, Wenyu Ding, et al.
Hepatology Communications (2025) Vol. 9, Iss. 2
Open Access
Liver diseases: epidemiology, causes, trends and predictions
Can Gan, Yuan Yuan, Haiyuan Shen, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access
Can Gan, Yuan Yuan, Haiyuan Shen, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access
Aurantio‐Obtusin Regulates Gut Microbiota and Serum Metabolism to Alleviate High‐Fat Diet‐Induced Obesity‐Associated Non‐Alcoholic Fatty Liver Disease in Mice
Zhen-Lin Li, Jin Yao, Hua-Shan Zhao, et al.
Phytotherapy Research (2025)
Closed Access
Zhen-Lin Li, Jin Yao, Hua-Shan Zhao, et al.
Phytotherapy Research (2025)
Closed Access
Μetabolic dysfunction-associated steatotic liver disease: a condition of heterogeneous metabolic risk factors, mechanisms and comorbidities requiring holistic treatment
Christopher D. Byrne, Angelo Armandi, Vanessa Pellegrinelli, et al.
Nature Reviews Gastroenterology & Hepatology (2025)
Closed Access
Christopher D. Byrne, Angelo Armandi, Vanessa Pellegrinelli, et al.
Nature Reviews Gastroenterology & Hepatology (2025)
Closed Access
Altered liver lipidome markedly overlaps with human plasma lipids at diabetes risk and reveals adipose-liver interaction
Ratika Sehgal, Markus Jähnert, Michail Lazaratos, et al.
Journal of Lipid Research (2025), pp. 100767-100767
Closed Access
Ratika Sehgal, Markus Jähnert, Michail Lazaratos, et al.
Journal of Lipid Research (2025), pp. 100767-100767
Closed Access
A Literature Review of Glutathione Therapy in Ameliorating Hepatic Dysfunction in Non-Alcoholic Fatty Liver Disease
M. Hong Nguyen, Andrew Lian, Frederick T. Guilford, et al.
Biomedicines (2025) Vol. 13, Iss. 3, pp. 644-644
Open Access
M. Hong Nguyen, Andrew Lian, Frederick T. Guilford, et al.
Biomedicines (2025) Vol. 13, Iss. 3, pp. 644-644
Open Access
Estimated sdLDL-C as a biomarker of hepatic steatosis severity in MASLD: a retrospective study
Shu Jiang, Fan Zhang, Huixia Yang, et al.
BMC Gastroenterology (2025) Vol. 25, Iss. 1
Open Access
Shu Jiang, Fan Zhang, Huixia Yang, et al.
BMC Gastroenterology (2025) Vol. 25, Iss. 1
Open Access
Pure total flavonoids from citrus alleviate oxidative stress and inflammation in nonalcoholic fatty liver disease by regulating the miR-137-3p/NOXA2/NOX2 pathway
Junbin Yan, Yunmeng Nie, Sumei Xu, et al.
Phytomedicine (2023) Vol. 118, pp. 154944-154944
Closed Access | Times Cited: 14
Junbin Yan, Yunmeng Nie, Sumei Xu, et al.
Phytomedicine (2023) Vol. 118, pp. 154944-154944
Closed Access | Times Cited: 14
